There's no sugar-coating it: GlaxoSmithKline (NYSE:GSK) had a pretty rough second quarter. U.S. sales of aging blockbuster Advair dropped by an astounding 19%, and Breo and Anora Ellipta, which have been hailed as potential blockbusters, turned in disappointing sales (5 million pounds each in the U.S.). Watch the video below for a quick take on earnings from Motley Fool health care analysts Michael Douglass and David Williamson.
Michael Douglass and Dave Williamson
Jul 24, 2014 at 4:30PM
Former Deputy Managing Editor, Fool.com. I started in Healthcare, but you'll find me writing regularly about biotech, dividend stocks, and personal finance.
Motley Fool Returns
Stock Advisor S&P 500
Stock Advisor launched in February of 2002. Returns as of 12/03/2020.Join Stock Advisor
Cumulative Growth of a $10,000 Investment in Stock Advisor Calculated by Time-Weighted Return